Guidelines for the treatment of arterial hypertension in diabetics: Consensus Recommendations of the German League for the Fight against High Blood Pressure, the German Diabetes Society and the Nephrological Society;Leitlinie zur behandlung der arteriellen hypertonie bei diabetes mellitus: Konsensus-Empfehlungen der Deutschen Liga zur Bekampfung des hohen Blutdruckes e.V., der Deutschen Diabetes Gesellschaft und der Gesellschaft fur Nephrologie

Deutsche Medizinische Wochenschrift

Volumn 124, Issue 45, 1999, Pages 1356-1372

  Schafers R F ^a   Lutkes P ^b   Ritz, E ^b   Philipp, Th ^b  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; AMILORIDE; ANGIOTENSIN ANTAGONIST; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CALCIUM ANTAGONIST; CANDESARTAN; CAPTOPRIL; CARVEDILOL; CHLORTALIDONE; DIHYDROPYRIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; HYDROCHLOROTHIAZIDE; INSULIN; LOSARTAN; METHYLDOPA; METOPROLOL; NADOLOL; POTASSIUM SPARING DIURETIC AGENT; PROPRANOLOL; SOTALOL; THIAZIDE DIURETIC AGENT; TIMOLOL; UNINDEXED DRUG;

COMORBIDITY; CONFERENCE PAPER; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DRUG CONTRAINDICATION; DRUG INDICATION; GERMANY; HUMAN; HYPERTENSION; PRACTICE GUIDELINE; PROGNOSIS; RISK FACTOR;

ANTIHYPERTENSIVE AGENTS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DRUG THERAPY, COMBINATION; GERMANY; HUMANS; HYPERTENSION; HYPOGLYCEMIC AGENTS; RISK FACTORS;

EID: 0033550184     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (216)

1. 1. Ahmad J, Siddiqui MA, Ahmad H. Effective postponement of diabetic nephropathy in IDDM patients with microalbuminuria. Diabetes Care. 1997;20:1576-81.
2. 2. Ambrosioni E, Borghi C, Magagni B, for the Survival of Mycardial Infarction Long-Term evaluation (SMILE) Study investigators. The effect of angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Eng J Med. 1995;332:80-85.
3. 3. American Diabetes Association. Nutrition recommendations and principles for people with diabetes mellitus. Diabetes Care. 1994;17:519-522.
4. 4. American Diabetes Association. ADA consensus statement. Treatment of hypertension in diabetes. Diabetes Care. 1996;19:S107-113.
5. 5. American Diabetes Association. Aspirin Therapy in Diabetes. Diabetes Care. 1999;22(Supplement 1):S60-S62.
6. 6. Andersen AR, Sandahl Christiansen J, Andersen JK, Kreiner S, Dekkert T. Diabetic nephropathy in type 1 (insulin-dependent) diabetes: an epidemiological study. Diabetologia. 1983;25:496-501.
7. 7. Aronson D, Rayfield EJ, Chesebro JH. Mechanisms determining course and outcome of diabetic patients who have had acute myocardial infarction. Ann Intern Med. 1997;126(4):296-306.
8. 8. Ballard DJ, Humphrey LL, Melton LJ, et al. Epidemiology of persistent proteinuria in type II diabetes mellitus. Population-based study in Rochester, Minnesota. Diabetes. 1988;37:405-412.
9. 9. Biesenbach G, Janko O, Zazgornik J. Similar rate of progression in the predialysis phase in type I and type II diabetes mellitus. Nephrol Dial Transplantat. 1994;9(8):1097-1102.
10. 10. Björck S, Mulec H, Johnsen SA, Norden G, Aurell M. Renal protective effect of enalapril in diabetic nephropathy. BMJ. 1992;304:339-343.
11. 11. Black HR. Metabolic considerations in the choice of therapy for the patient with hypertension. Am. Heart J. 1991;121:707-715.
12. 12. Borch-Johnsen K, Andersen PK, Deckert T. The effect of proteinuria on relative mortality in type 1 (insulin-dependent) diabetes mellitus. Diabetologia. 1985;28:590-596.
13. 13. Borch-Johnson K, Nissen R, Nerup J. Blood pressure after 40 years of insulin-dependent diabetes. Nephron. 1985;4:11-12.
14. 14. Broeckel U, Shiozawa M, Kissebah AH, Provoost AP, Jacob HJ. Susceptibility genes for end-organ damage. New strategies to understand diabetic and hypertensive nephropathy. Nephrol Dial Transplant. 1998;13(4):840-842.
15. 15. Burt VL, Whelton P, Rocella EJ, et al. Prevalence of hypertension in the US adult population: results from the third National Health and Nutrition Examination Survey, 1988-1991. Hypertension. 1995;25:305-313.
16. 16. Cambien F, Evans A. Angiotensin I converting enzyme gene polymorphism and coronary heart disease. Eur Heart J. 1995;16 Suppl K:13-22.
17. 17. Carlsen JE, Kober L, Torp-Pedersen C, Johansen P. Relation between dose of bendrofluazide, antihypertensive effect, and adverse biochemical effects. BMJ. 1990;300:975-978.
18. 18. Chan JCN, Cockram CS, Nicholls MG, Cheung CK, Swaminathan R. Comparison of enalapril and nifedipine in treating non-insulin dependent diabetes associated with hypertension: one year analysis. BMJ. 1992;305:981-985.
19. 19. Christlieb AR, Warram JA, Krolewski AS, et al. Hypertension: The major risk factor in juvenile-onset insulin-dependent diabetics. Diabetes. 1981;30(Suppl. 2):90-96.
20. 20. Chun BY, Dobson AJ, Heller RF. The impact of diabetes on survival among patients with first myocardial infarction. Diabetes Care. 1997;20(5):704-708.
21. 21. Ciavarella A, Di Mizio G, Stefoni S, Borgnino LC, Vannini P. Reduced albuminuria after dietary protein restriction in insulin-dependent diabetic patients with clinical nephropathy. Diabetes Care. 1987;10:407-413.
22. 22. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353:9-13.
23. 23. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet. 1990;335: 827-838.
24. 24. Cruickshank JM, Thorp JM, Zacharias FJ. Benefits and potential harm of lowering high blood pressure. Lancet. 1987;1(8533):581-584.
25. 25. Curb JD, Pressel SL, Cutler JA, et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. JAMA. 1996;276(23):1886-1892.
26. 26. Dahlöf B, Lindholm LH, Hansson L, Schersten B, Ekbom T, Wester PO. Morbidity and mortality in the swedish trial in old patients with hypertension (STOP-Hypertension). Lancet. 1991;338:1282-1285.
27. 27. Damsgaard EM, Froland A, Jorgensen OD, Mogensen CE. Microalbuminuria as predictor of increased mortality in elderly patients. BMJ. 1990;300:297-300.
28. 28. Deckert T, Poulsen JE, Larsen M. Prognosis of diabetics with diabetes onset before the age of thirtyone. I. Survival, causes of death and complications. Diabetologia. 1978;14:363-370.
29. 29. Diabetes Nutrition Study Group of the European Association for the study of Diabetes. Recommendations for the nutritional management of patients with diabetes mellitus. Diab Nutr Metabol. 1995;8:186-189.
30. 30. Dodson PM, Beevers M, Hallworth R, Webberley MJ, Fletcher RF, Taylor KG. Sodium restriction and blood pressure in hypertensive type II diabetics: randomised blind controlled and crossover studies of moderate sodium restriction and sodium supplementation. BMJ. 1989;298:227-230.
31. 1-Adrenozeptorenblocker in der Hochdrucktherapie. Internist. 1993;34:682-687.
32. 32. Dullaart RPF, Beusekamp BJ, Meijer S, van Doormaal JJ. Long-term renal effects of protein-restricted diet in type 1 (insulin-dependent) diabetic patients without clinical nephropathy and hypertension. Diabetologia. 1992;35(Suppl. 1):A148 (Abstract).
33. 33. Egger M, Davey SG, Stettler C, Diem P. Risk of adverse effects of intensified treatment in insulin-dependent diabetes mellitus: a meta-analysis. Diabet Med. 1997;14(11):919-928.
34. 34. Ekstrand K, Bostrom PA, Lilja B, Hansen O, Arborelius M, Jr. Submaximal early exercise test compared to clinical findings for evaluation of short-and long-term prognosis after the first myocardial infarction. Result from the MONICA Projects in Augsburg and Toulouse. Eur Heart J. 1997;18(5):822-834.
35. 35. Epstein M. Diabetes and hypertension: the bad companions. J Hypertens Suppl. 1997;15(2):S55-S62.
36. 36. Epstein M, Sowers JR. Diabetes mellitus and hypertension. Hypertension. 1992;19:403-418.
37. 37. Equiluz-Bruck S, Schnack C, Kopp HP, Schernthaner G. Nondipping of nocturnal blood pressure is related to urinary albumin excretion rate in patients with type 2 diabetes mellitus. Am J Hypert. 1996;9:1139-1143.
38. 38. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med. 1998;338(10):645-652.
39. 39. European Diabetes Policy Group 1998. A Desktop Guide to Type 1 (Insulin-dependent) Diabetes Mellitus. Experimental and Clinical Endocrinology & Diabetes. 1998;106:240-269.
40. 40. European Working Party on Hypertension in the Elderly (EWPHE). Glucose intolerance during diuretic therapy. Lancet. 1978;ii:681-683.
41. 41. Fogarty DG, Krolewski AS. Genetic susceptibility and the role of hypertension in diabetic nephropathy. Curr Opin Nephrol Hypertens. 1997;6(2):184-191.
42. 42. Forsblom CM, Groop P-H, Ekstrand A, et al. Predictors of progression from normoalbuminuria to microalbuminuria in NIDDM. Diabetes Care. 1998;21:1932-1938.
43. 43. Frei U, Schober-Halstenberg HJ. (Projektgeschäftsstelle QuaSi Niere). Nierenersatztherapie in Deutschland QuaSi Niere. 1996 Juli 1998.
44. 44. Frost D, Pfohl M, Clemens P, Haring HU, Beischer W. Evaluation of the insertion/deletion ACE gene polymorphism as a risk factor for carotid artery intima-media thickening and hypertension in young type 1 diabetic patients. Diabetes Care. 1998;21(5):836-840.
45. 45. Gansevoort RT, Sluiter WJ, Hemmelder MH, de Zeeuw D, de Jong PE. Antiproteinuric effect of blood-pressure-lowering agents: a meta-analysis of comparative trials. Nephrol. Dial. Transplant. 1995;10:1963-1974.
46. 46. Goldner MG, Zarowitz H, Akgun S. Hyperglycemia and glycosuria due to thiazide derivatives administered in diabetes mellitus. N. Engl. J. Med. 1960;262:403-405.
47. 47. Gomez-Perez FJ, Aguilar-Salinas CA, Lopez-Alvarenga JC, Perez-Jauregi J, Guillen-Pineda LE, Rull JA. Lack of agreement between the World Health Organization Category of impaired glucose tolerance and the American Diabetes Association category of impaired fasting glucose. Diabetes Care. 1998;21(11):1886-8.
48. 48. Goto Y, Tamachi H. Antihypertensive therapy and the lipid risk factor. In: Bühler FR, Laragh JH, eds. The management of hypertension. Vol. 13. Amsterdam New York Oxford: Elsevier; 1990;362-378.
49. 49. Griffin S, Kinmonth AL. Diabetes care: the effectiveness of systems for routine surveillance for people with diabetes (Cochrane Review). . The Cochrane Library, Vol. Issue 1 : 1999.
50. 50. Grodstein F, Stampfer MJ, Manson JE, al. e. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Eng J Med. 1996;335:453-461.
51. 51. Grossmann E, Messerli FH. Diabetic and hypertensive heart failure. Ann Int Med. 1996;125:304-310.
52. 52. Gundersen T, Kjekshus J. Timolol treatment after myocardial infarction in diabetic patients. Diabetes Care. 1983;6:285-290.
53. 53. Haffner SM. The Scandinavian Simvastatin Survival Study (4S) subgroup analysis of diabetic subjects:implications for the prevention of coronary heart disease. Diabetes Care. 1997;20(4):469-471.
54. 54. Haffner SM. Management of dyslipidemia in adults with diabetes. Diabetes Care. 1998;21(1):160-178.
55. 55. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and nondiabetic subjects with and without prior myocardial infarction. New Eng J Med. 1998;339(4):229-34.
56. 56. Hallab M, Gallois Y, Chatellier G, Rohmer V, Fressinaud P, Marre M. Comparison of reduction in microalbuminuria by enalapril and hydrochlorothiazide in normotensive patients with insulin dependent diabetes. BMJ. 1993;306:175-182.
57. 57. Hansen KW, Poulsen PL, Ebbehoj E. Blood pressure elevation in diabetes: the results from 24-h ambulatory blood pressure recordings. In: Mogensen CE, ed. The kidney and hypertension in diabetes mellitus. 4. ed. Boston, Dordrecht, London: Kluwer Academic Publisher; 1998:335-356.
58. 58. Hansson L. The captopril prevention project (CAPP). Am J Hypert. 1999;7(Suppl):82-83.
59. 59. Hansson L, Zanchetti A, Carruthers SG, et al. Effect of intensive blood pressure lowering and low-dose aspirin in patients with hypertension:principle results of the hypertension optimal treatment (HOT) randomised trial. Lancet. 1998;351:1755-1762.
60. 60. Harris MI, Eastman RC, Cowie CC, Flegal KM, Eberhardt MS, Comparison of Diabetes Diagnostic Categories in the US population according to 1997 American Diabetes Association and 1980 - 1985 World Health Organization Diagnostic Criteria. Diabetes Care. 1997;20(12):1859-1862.
61. 61. Hasslacher C. Frühdiagnose der diabetischen Nephropathie. Deutsches Ärzteblatt 96(1-2): A-51-53.
62. 62. Hasslacher C, Borgholte G, Panradl U, Wahl P. Verbesserte Prognose von Typ-I-und Typ-II-Diabetikern mit Nephropathie. Med. Klin. 1990;85:643-646.
63. 63. Hasslacher C, Bostedt-Kiesel A, Kempe HP, Wahl P. Effect of metabolic factors and blood pressure on kidney function in proteinuric Type 2 (non-insulin-dependent) diabetic patients. Diabetologia. 1993;36:1051-1056.
64. 64. Hasslacher C, Ritz E, Tschope W, Gallasch G, Mann JF. Hypertension in diabetes mellitus. Kidney Int Suppl. 1988;34(Suppl 25):S133-S137.
65. 65. Hasslacher C, Ritz E, Wahl P, Michael C. Similar risks of nephropathy in patients with type I or type II diabetes mellitus. Nephrol. Dial. Transplant. 1989;4:859-863.
66. 66. Hebert LA, Kusek JW, Greene T, et al. Effects of blood pressure control on progressive renal disease in blacks and whites. Modification of Diet in Renal Disease Study Group, Hypertension. 1997;30(3 Pt 1):428-435.
67. 67. Herzog CA, Ma JZ, Collins AJ. Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. New Eng J Med. 1998;339(12):799-805.
68. 68. Hirsch IB, Boyle PJ, Craft S, Cryer PE. Higher glycemic thresholds for symptoms during ß-adrenergic blocade in IDDM. Diabetes. 1991;40:1177-1186.
69. 69. Hirschl MM, Heinz G, Sunder-Plassmann G, Derfler K. Renal Replacement therapy in type 2 diabetic patients: 10 years' experience. Am J Kidney Dis. 1992;20(6):564-568.
70. 70. Hörner D, Fliser D, Klimm HP, Ritz E. Albuminuria in normotensive and hypertensive individuals attendig offices of general practitioniers. J Hypertens. 1996;14:655-660.
71. 71. Hultberg B, Isaksson A, Brattström L, Israelsson B. Elevated urinary excretion of ß-hexosaminidase in smokers. Eur J Clin Chem Clin Biochem. 1992;30:131-133.
72. 72. Jacobson HR, Striker GE. Report on a workshop to develop management recommendations for the prevention of progression in chronic renal disease. Am J Kidney Dis. 1995;25(1):103-106.
73. 73. Jarrett RJ, Viberti GC, Argyropoulos A. Microalbuminuria predicts mortality in non-insulin-dependent diabetes. Diabetic Med. 1984;1:17-19.
74. 74. Johnston CI, Cooper ME, Nicholls GM. Meeting report of the international society of hypertension conference on hypertension and diabetes. J. Hypertens. 1992;10:393-397.
75. 75. Kalra PA, Kumwenda M, MacDowall P, Roland MO. Questionnaire study and audit of use of angiotensin converting enzyme inhibitor and monitoring in general practice: the need for guidelines to prevent renal failure. BMJ. 1999;318:234-7.
76. 76. Kannel WB. Atherosclerosis risk factors. Pharmac. Ther. 1987;32:207-235.
77. 77. Kasiske BL, Kalil RSN, Ma JZ, Liao M, Keane WF. Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann. Int. Med. 1993;1993:129-138.
78. 78. Kasiske BL, Lakatua JD, Ma JZ, Louis TA. A meta-analysis of the effects of dietary protein restriction on the rate of decline in renal function. Am J Kidney Dis. 1998;31(6):954-961.
79. 79. Keavney BD, Dudley CR, Stratton IM, et al. UK prospective diabetes study (UKPDS) 14: association of angiotensin-converting enzyme insertion/deletion polymorphism with myocardial infraction in NIDDM. Diabetologia. 1995;38(8):948-952.
80. 80. Keil U, Liese AD, Hense HW, et al. Classical risk factors and their impact on incident non-fatal and fatal myocardial infarction and all-cause mortality in southern Germany. Results from the MONICA Augsburg cohort study 1984-1992. Monitoring Trends and Determinants in Cardiovascular Diseases. Eur Heart J. 1998;19(8): 1197-1207.
81. 81. Keller CK, Bergis KH, Fliser D, Ritz E. Renal findings in patients with short-time type 2 diabetes. J Am Soc Nephrol. 1996;7(12):2627-35.
82. 82. Kjekshus J, Gilpin E, Cali G, Blackey AR, Henning H, Ross J. Diabetic-patients and beta-blockers after acute myocardial infarction. Eur. Heart J. 1990;11:43-50.
83. 83. Klahr S, Levey AS, Beck GJ. for the Modification of Diet in Renal Disease Study Group. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. New Engl J Med. 1994;330:877-884.
84. 84. Klein R, Moss SE, Klein BEK, DeMets DL. Relation of ocular and systemic factors to survival in diabetes. Arch. Intern. Med. 1989;149:266-272.
85. 85. Ko GT, Chan JC, Woo J, Cockram CS. Use of the 1997 American Diabetes Association diagnostic criteria for diabetes in a Hong Kong Chinese Population, Diabetes Care. 1998;21(12):2094-7.
86. 86. Kober L, Torp-Pedersen C, Carlssen JE, et al. A clinical trial of the angiotensin-converting enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. New Engl J Med. 1995;333:1670-1676.
87. 87. Koch M, Kutkuhn B, Grabensee B, Ritz E. Apolipoprotein A, fibrinogen, age, and history of stroke are predictors of death in dialysed diabetic patients:a prospective study in 412 patients. Nephrol Dial Transplantat. 1997;12(12):2603-2611.
88. 88. Kribben A, Anlauf M, Distler A, et al. Hydrochlorothiazide, atenolol, nitrendipine, and enalapril in antihypertensive treatment. Influence on LVH, proteinurie and metabolic parameters. The HANE Trial Research Group. Kidney Int Suppl. 1997;61:S74-76.
89. 89. Laffel LMB, McGill JB, Gans DJ. The beneficial effect of angiotensinconverting-enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. Am J Med. 1995;99:497-504.
90. 90. Lager I, Smith U, Blohme G. Effect of cardioselective and non-selective ß-blockade on the hypoglycemic response in insulin-dependent diabetics. Lancet. 1979;458-462.
91. 91. Lever AF, Brennan PJ. MRC trial of treatment in elderly hypertensives. Clin Exp Hypertens. 1993;15:941-942.
92. 92. Lewis FJ, Hunsicker LG, Bain RP, Rohde RD, for the Collaborative Study Group. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N. Engl. J. Med. 1993;329:1456-1462.
93. 93. Lippert J, Ritz E. Schwarzbeck A, Schneider P. The rising tide of endstage renal failure from diabetic nephropathy type II - an epidemiological analysis. Nephrol Dial Transplant. 1995;10(4):462-467.
94. 94. Lithell H. The effect of ACE inhibitors and other antihypertensive agents on insulin resistance. Nephrol. Dial. Transplant. 1995;10:589-591.
95. 95. Lithell HO. Considerations in the treatment of insulin resistance and related disorders with a new sympatholytic agent. J Hypert Suppl. 1997;15(1):S39-42.
96. 96. Locatelli F, Alberti D, Graziani G, et al. Prospective randomized multicentre trial of effect of protein restriction on progression of chronic renal insufficiency. Lancet. 1991;337:1299-1304.
97. 97. Locatelli F, Del Vecchio L, Manzoni C. Morbidity and mortality on maintenance hemodialysis. Nephron. 1998;80(4):380-400.
98. 98. Lydakis C, Lip GY. Microalbuminuria and cardiovascular risk. QJM. 1998;91(6):381-391.
99. 99. Marcelli D, Spotti D, Conte F, et al. Prognosis of diabetic patients an dialysis: analysis of Lombardy Registry data. Nephrol Dial Transplant. 1995;10(10):1895-1900.
100. 100.Marre M, Chatellier G, Leblanc H. Guyene TT, Menard J, Passa P. Prevention of diabetic nephropathy with enalapril in normotensive diabetics with microalbuminuria. BMJ. 1988;297:1092-1095.
101. 101.Maschio G, Alberti D, Janin G, et al. Effect of the Angiotensin-Converting-Enzyme Inhibitor Benazepril on the Progression of Chronic Renal Insufficiency. NEJM. 1996;334:939-945.
102. 102.Mathiesen ER, Borch-Johnsen K, Jensen DV, Deckert T. Improved survival in patients with diabetic nephropathy. Diabetologia. 1989;32:884-886.
103. 103.Mathiesen ER, Hommel E, Giese J, Parving HH. Efficacy of captopril in postponing nephropathy in normotensive insulin dependent diabetic patients with microalbuminuria. BMJ. 1991;303:81-87.
104. 104.Medical Research Council Working Party on Mild to Moderate Hypertension. Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension. Lancet. 1981;ii:539-543.
105. 105.MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic he art failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353:2001-2007.
106. 106.Miettinen H, Lehto S, Salomaa V, et al. Impact of diabetes on mortality after the first myocardial infarction. The FINMONICA Myocardial Infarction Register Study Group. Diabetes Care. 1998;21(1):69-75.
107. 107.Mogensen CE. Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy. BMJ. 1982;285:685-688.
108. 108.Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity onset diabetes. New Engl. J. Med. 1984;310:356-360.
109. 109.Mogensen CE. Microalbuminuria, blood pressure and diabetic renal disease: origin and development of ideas. Diabetologia. 1999;42:263-285.
110. 110.Mogensen CE, Christensen CK. Predicting diabetic nephropathy in insulin-dependent patients. N. Engl. J. Med. 1984;311:89-93.
111. 111.Mogensen CE, Christensen CK, Vittinghus E. The stages in diabetic renal disease - With emphasis on the stage of incipient diabetic nephropathy. Diabetes. 1983;32(Suppl. 2):64-78.
112. 112.Mogensen CE, Kenne WF, Bennett PH, et al. Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet. 1995;346(8982):1080-1084.
113. 113.Moller DE, Bjorbaek C, Vidal-Puig A. Candidate genes for insulin resistance. Diabetes Care. 1996;19(4):396-400.
114. 114.Morris BJ. Insulin receptor gene in hypertension. Clin Exp Hypertens. 1997;19(5-6):551-565.
115. 115.MRC Working Party. Medical research council trial of treatment of hypertension in older adults: principal results. BMJ. 1992;304:405-412.
116. 116.Mühlhauser I, Prange K, Sawicki PT, et al. Effects of dietary sodium on blood pressure in IDDM patients with nephropathy. Diabetologia. 1996;39:212-219.
117. 117.Nakano S, Fukuda M, Hotta F, et al. Reversed circadian blood pressure rhythm is associated with occurences of both fatal and nonfatal vascular events in NIDDM subjects. Diabetes. 1998:47:1501-1506.
118. 118.Nielsen FS, Gaede P, Vedel P, Pedersen O, Parving HH. White coat hypertension in NIDDM patients with and without incipient and overt diabetic nephropathy. Diabetes Care. 1997;20(5):859-863.
119. 119.Nielsen S, Schmitz A, Rehling M, Mogensen CE. Systolic blood pressure determines the rate of decline of glomerular filtration rate in Type 2 (non-insulin-dependent) diabetes mellitus. Diabetes Care. 1993;16:1427-1432.
120. 120.O'Donnell MJ, Rowe B, Lawson N, Horton A, Gyde OHB, Barnett AH. Placebo controlled study of lisinopril in normotensive diabetic patients with microalbuminuria. Diabetologia. 1992;35(Suppl. 1):A148 (Abstract).
121. 121.Orth SR, Ritz E. Rauchen - ein Risikofaktor für die Progression primärer und sekundärer Nierenerkrankungen. Diabetes und Stoffwechsel. 1998;7:60-64.
122. 122.Orth SR, Ritz E, Schrier RW. The renal risks of smoking. Kidney Int. 1997;51:1669-1677.
123. 123.Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 1996;334:1349-1355.
124. 124.Pacy PJ, Dodson PM, Kubicki AJ, Fletcher RF, Taylor KG. Comparison of the hypotensive and metabolic effects of bendrofluazide therapy and a high fibre, low fat, low sodium diet in diabetic subjects with mild hypertension. J. Hypertens. 1984;2:215-220.
125. 125.Pacy PJ, Dodson PM, Kubicki AJ, Fletcher RF, Taylor KG. Comparison of the hypotensive and metabolic effects of metoprolol therapy with a high fibre, low sodium, low fat diet in hypertensive type 2 diabetic subjects. Diabetes Res. 1984;1:201-207.
126. 126.Parving H-H, Andersen AR, Smidt UM, Hommel E, Mathiesen ER, Svendsen PA. Effect of antihypertensive treatment on kidney funtcion in diabetic nephropathy. BMJ. 1987;294:1443-1447.
127. 127.Parving H-H, Hommel E. Prognosis in diabetic nephropathy. BMJ. 1989;299:230-233.
128. 128.Parving H-H, Hommel E, Smidt UM. Protection of kidney function and decrease in albuminuria by captopril in insulin dependent diabetics with nephropathy. BMJ, 1988;297:1086-1091.
129. 129.Parving H-H, Rossing P, Hommel E, Smidt UM. Renal protective effects of captopril and metoprolol in diabetic nephropathy. Diabetologia. 1992;35(Suppl. 1):A148 (Abstract).
130. 130.Pedrini MT, Levey AS, Lau J, Chalmers TC, Wang PH. The effect of dietary protein restriction on the progression of diabetic and non-diabetic renal diseases: a meta-analysis. Ann Intern Med. 1996;124(7):627-632.
131. 131.Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. 1992;327:669-677.
132. 132.Pietruck F, Moritz A, Montemurro M, et al. Selectively enhanced cellular signalling by G(i)proteins in essential hypertension. Galpha(i2), Galpha(i3), Gbeta(1) and Gß(2) are not mutated. Circ Res. 1996;79:974-983.
133. 133.Pitt B, Segal R, Martinez FA, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (ELITE). Lancet. 1997;349:747-752.
134. 134.Pollare T, Lithell H, Berne C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N. Engl. J. Med. 1989;321:868-873.
135. 135.Pool JL. Effects of doxazosin on serum lipids: A review of the clinical data and molecular basis for altered lipid metabolism. Am Heart J. 1991;121:251-60.
136. 136.Poulsen PL, Bek T, Ebbehoj E, Hansen KW, Mogensen CE. 24-h ambulatory blood pressure and retinopathy in normoalbuminuric IDDM patients. Diabetologia. 1998;41:105-110.
137. 137.Poulsen PL, Ebbehoi E, Hansen KW, Mogensen CE. 24-hour blood pressure and autonomie function is related to albumin excretion within the normoalbuminuric range in IDDM patients. Diabetologia. 1997;40:718-25.
138. 138.Pujia A, Gnasso A, Irace C, et al. Association between ACE-D/D polymorphism and hypertension in type II diabetic subjects. J Hum Hypertens. 1994;8(9):687-691.
139. 139.Ravid M, Brosh D, Levi Z, Bar-Dayan Y, Ravid D, Rachmani R. Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med. 1998;128(12 Pt 1):982-988.
140. 140.Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann. Intern. Med. 1993;118:577-581.
141. 141.Reichard P, Nilsson BY, Rosenquist U. The effect of long-term intensified insulin treatment in the development of microvascular complications of diabetes mellitus. N. Engl. J. Med. 1993;329:304-309.
142. 142.Rett K, Lotz N, Wicklmayr M, et al. Verbesserte Insulinwirkung durch ACE-Hemmung beim Typ-II-Diabetiker, Dtsch. med. Wschr. 1988;113:243-249.
143. 143.Rett K, Wicklmayr M, Dietze GJ. Hypoglycemia in hypertensive diabetic patients treated with sulfonylureas, biguanides, and captopril [letter]. N Engl J Med. 1988;319(24):1609.
144. 144.Rudberg S, Aperia A, Freyschuss U, Persson B. Enalapril reduces microalbuminuria in young normotensive Type 1 (insulin-dependent) diabetic patients irrespective of its hypotensive effect. Diabetologia. 1990;33:470-476.
145. 145.Runyan JW. Influence of thiazide diuretics on carbohydrate metabolism in patients with mild diabetes. N. Engl. J. Med. 1962;267:541-543.
146. 146.Rychlik I, Miltenberger-Miltenyi G, Ritz E. The drama of the continuous increase in end-stage renal failure in patients with type II diabetes mellitus. Nephrol Dial Transplant. 1998;13(Suppl 8):6-10.
147. 147.Sagie A, Larson MG, Levy D. The natural history of borderline isolated systolic hypertension. N Eng J Med. 1993;329:1912-1917.
148. 148.Samuelsson O, Wilhelmsen L, Elmfeldt D, et al. Predictors of cardiovascular mortality in treated hypertension: results from the Primary Preventive Trial in Göteborg, Sweden. J Hypertens. 1985;3:167-176.
149. 149.Sawicki PT, Didjurgeit U, Mühlhauser I, Bender R, Heinemann L, Berger M. Smoking is associated with progression of diabetic nephropathy. Diabetes Care. 1994;17:126-131.
150. 150.Sawicki PT, Kaiser S, Ehle B, Frenzel H, Berger M. Post-mortem-Untersuchung zur Häufigkeit von Nierenarterienstenosen bei Parienten mit Diabetes mellitus. Akt. Endokr. Stoffw. 1989;10:125 (Abstrakt).
151. 151.Sawicki PT, Kaiser S, Heinemann L, Frenzel H, Berger M, Prevalence of renal artery stenosis in diabetes mellitus. J Int Med. 1991;229:489-492.
152. 152.Sawicki PT, Mühlhauser I, Bender W, Pethke W, Heinemann L, Berger M. Effects of smoking on blood pressure and proteinuria in patients with diabetic nephropathy. J Int Med. 1996;239:345-352.
153. 153.Sawicki PT, Mühlhauser I, Didjurgeit U, Bender R, Berger M, Intensivierte antihypertensive Therapie versus konventionelle Betreuung von Typ-1 Diabetikern mit manifester diabetischer Nephropathie. 17. Tagung der Wissenschaftlichen Sektion der Deutschen Liga zur Bekämpfung des hohen Blutdruckes in Verbindung mit dem Arbeitskreis Deutscher Lipidforscher. Essen 27, bis 30, Oktober 1993. 1993:Abstract 113.
154. 154.Sawicki PT, Muhlhauser I, Didjurgeit U, Reimann M, Bender R, Berger M. Mortality and morbidity in treated hypertensive type 2 diabetic patients with micro-or macroproteinuria. Diabet Med. 1995;12(10):893-898.
155. 155.Schernthaner G, Ritz E, Philipp T, Bretzel R. Die Bedeutung der 24-Stunden-Blutdruckmessung bei Patienten mit Diabetes mellitus. Deutsch Med Wochenschrift. 1999, 124(13), 393-395.
156. 156.Scrimieder RE, Schlaich MP, Klingbeil AU, Martus P. Update on reversal of left ventricular hypertrophy in essential hypertension (a meta-analysis of all randomized double-blind studies until december 1996). Nephrol Dial Transplantation. 1998;13(3):564-9.
157. 157.Schmitz A. Microalbuminuria, blood pressure, metabolic control, and renal involvement.Longitudinal studies in white non-insulin-dependent diabetic patients. Am J Hypert. 1997;10:189S-197S.
158. 158.Schmitz A, Vaeth M, Mogensen CE. Systolic blood pressure relates to the rate of progression of albuminuria in NIDDM. Diabetologia. 1994;37:1251-1258.
159. 159.Sharma AM. The thrifty-genotype hypothesis and its implications for the study of complex genetic disorders in man. J Mol Med. 1998;76(8):568-571.
160. 160.SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA. 1991;265:3255-3264.
161. 161.Siffert W, Dusing R. Na+/H+ exchange in hypertension and in diabetes mellitus - facts and hypotheses. Basic Res Cardiol. 1996;91(3):179-190.
162. 162.Simonson DC. Etiology and prevalence of hypertension in diabetic patients. Diabetes Care. 1988;11:821-827.
163. 163.Siscovick DS, Raghunathan TE, Psaty BM, et al. Diuretic therapy for hypertension and the risk of primary cardiac arrest. N. Engl. J. Med. 1994;330:1852-1857.
164. 164.Slataper R, Vicknair N, Sadler R, Bakris GL. Comparative effects of different antihypertensive treatments on progression of diabetic renal disease. Arch. Intern. Med. 1993;153:973-980.
165. 165.Sourander L, Rajala T, Räihä I, Mäkinen J, Erkkola R, Helenius H. Cardiovascular and cancer morbidity and mortality and sudden cardiac death in postmenopausal women on oestrogen replacement therapy (ERT). Lancet. 1998;352:1965-69.
166. 166.Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet. 1997;350:757-764.
167. 167.Stamler R, Stamler J, Grimm R, et al. Nutritional therapy for high blood pressure. Final report of a four-year randomized controlled trial - The hypertension control program. JAMA. 1987;257:1484-1491.
168. 168.Stampfer MJ, Colditz GA, Willett WC, et al. Postmenopausal estrogen therapy and cardiovascular disease: ten years follow-up from the Nurses' Health study. New Engl J Med. 1991;325:756-62.
169. 169.Standl E, Balletshofer B, Dahl B, et al. Predictors of 10-year macrovascular and overall mortality in patients with NIDDM: the Munich General Practioner Project. Diabetologia. 1996;39:1540-1545.
170. 170.Standl E, Stiegler H. Microalbuminuria in a random cohort of recently diagnosed Type 2 (non-insulin-dependent) diabetic patients living in the Greater Munich Area, Diabetologia. 1993;36:1017-1020.
171. 171.Standl E, Stiegler H, Roth R, Schulz K, Lehmacher W. On the impact of hypertension on the prognosis of NIDDM. Results of the Schwabing GP-Program. Diabete Metab. 1989;15:352-358.
172. 172.Stiegler H, Standl E, Schulz K, Roth R, Lehmacher W. Morbidity. Mortality, and Albuminuria in Type 2 Diabetic Patients: a three-year Prospective Study of a random Cohort in General Practice. Diabetic Medicine. 1992;9:646-653.
173. 173.Strojek K, Grzeszczak W, Lacka B, Gorska J, Keller CK, Ritz E. Increased prevalence of salt sensitivity of blood pressure in IDDM with and without microalbuminuria. Diabetologia. 1995;38(12):1443-1448.
174. 174.Strojek K, Grzeszczak W, Morawin E, et al. Nephropathy of type II diabetes: evidence for hereditary factors? Kidney Int. 1997;51(5):1602-1607.
175. 175.Sturrock ND, Pound N, Peck GM, Soar CM, Jeffcoate WJ. An assessment of blood pressure measurement in a diabetic clinic using random-zero, semi-automated and 24-hour monitoring. Diabet Med. 1997;14:370-375.
176. 176.Tanaka Y, Atsumi Y, Matsuoku K, Onuma T, Tohjima T, Kawamori R. Role of glycemic control and blood pressure in the development and progression of nephropathy in elderly Japanese NIDDM patients. Diabetes Care. 1998;21:116-120.
177. 177.Tatti P, Pahor M, Byington RP, et al. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care. 1998;21(4):597-603.
178. 178.The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 1993;342:821-828.
179. 179.The CONSENSUS trial study group. Effects of enalapril on mortality in severe congestive heart failure; results of the cooperative north Scandinavian enalapril survival study (CONSENSUS). N. Engl. J. Med. 1987;316:1429-1435.
180. 180.The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 1993;329:977-986.
181. 181.The Diabetes Control and Complications Trial Research Group. Hypoglycemia in the Diabetes Control and Complications Trial. The Diabetes Control and Complications Trial Research Group. Diabetes. 1997;46(2):271-286.
182. 182.The EUCLID study group. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet. 1997;349:1787-92.
183. 183.The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 1999;22(Supplement 1).
184. 184.The GISEN Group. Randomised placebo-controlled trail of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet. 1997;349:1857-1863.
185. 185.The Hypertension in Diabetes Study Group. Hypertension in diabetes study (HDS): I. Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications. J. Hypertens. 1993;11:309-317.
186. 186.The Hypertension in Diabetes Study Group. Hypertension in diabetes study (HDS): II. Increased risk of cardiovascular complications in hypertensive type 2 diabetic patients. J. Hypertens. 1993;11:319-325.
187. 187.The Microalbuminuria Captopril Study Group. Captopril reduces the risk of nephropathy in IDDM patients with microalbuminuria. Diabetologia. 1996;39:587-593.
188. 188.The National High Blood Pressure Education Program Coordinating Committee. (National Heart, Lung, and Blood institute). The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. 1997. Report No.: 6.
189. 189.The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N. Engl. J. Med. 1991;325:293-302.
190. 190.Tierney WM, Harris LE, Copley JB, Luft FC. Effect of hypertension and type II diabetes on renal function in an urban population. Am J Hypertens. 1990;3(1):69-75.
191. 191.Tierney WM, McDonald CJ, Luft FC. Renal disease in hypertensive adults: effect of race and type II diabetes mellitus. Am J Kidney Dis. 1989;13(6):485-493.
192. 192.Toeller M, Buyken A, Heitkamp G. Protein intake and urinary albumin excretion rates in the EURODIAB IDDM Complications Study. Diabetologia. 1997;40:1219-1226.
193. 193.Trenkwalder P, Dahl K, Lehtovirta M, Mulder H. Antihypertensive treatment with candesartan cilexetil does not affect glucose homeostasis or serum lipid profile in patients with mild hypertension and type II diabetes. Blood Press. 1998;7(3):170-175.
194. 194.Trocha AK, Schmidtke C, Didjurgeit U, et al. Impact of Intensified Antihypertensive treatment on prognosis of Type 1 patients with overt nephropathy - a controlled prospective 10 years follow-up study. Kidney Blood Pressure Research. 1998;21:388 (Abstract).
195. 195.Tschoepe D. The Activated Megakaryocyte-Platelet System in Vascular Disease. Semin Thromb Hemostas. 1995;21:152-159.
196. 196.Tschoepe D, Lampeter E, Schwibbert B. Megakaryocytes and Platelets in Diabetes Mellitus. Hämostaseologic. 1996;16:144-150.
197. 197.Tschoepe D, Rauch U, Schwibbert B. Platelet-Leukocyte-Cross-Talk in Diabetes Mellitus. Horm Metab Res. 1997;29:631-635.
198. 198.Tschoepe D, Roesen P. Heart disease in diabetes mellitus: a challenge for early diagnosis and intervention. Exp Clin Endocrinol Diabetes. 1998;106(1):16-24.
199. 199.Tschoepe D, Schwippert B, Raic I, Schmidt-Soltau C, Rösen P. Wirkung von Acetyl-Salicyl-Säure auf die intravasale Thrombozytenaktivierung von Typ-I-Diabetikern. Diab Stoffw. 1994;3:391-396.
200. 200.Tuomilheto J, Rastenyte D, Birkenhäger WH, et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. New Engl J Med. 1999;340(9):677-684.
201. 201.Turner RC, Levy JC, Clark A. Complex genetics of type 2 diabetes: thrifty genes and previously neutral polymorphisms. Q J Med. 1993;86(7):413-417.
202. 202.UK Prospective Diabetes Study (UKPDS) Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. BMJ. 1998;317(7160):713-720.
203. 203.UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):837-853.
204. 204.UK Prospective Diabetes Study (UKPDS) Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ. 1998;317(7160):703-713.
205. 205.United States Renal Data System. (National Institute of Diabetes and Digestive and Kidney Disease). The USRDS 1998 Annual Data Report. 1998.
206. 206.Viberti G, Mogensen CE, Groop LC, Pauls JF. Effect of captopril on progression to clinical proteinuria in patients with insulin dependent diabetes mellitus and microalbuminuria. European microalbuminuria captopril study group. JAMA. 1994;271:275-279.
207. 207.Viberti GC, Earle K. Predisposition to essential hypertension and the development of diabetic nephropathy. J Am Soc Nephrol. 1992;3(4 Suppl):S27-33.
208. 208.Walker JD, Dodds RA, Murrells TJ, et al. Restriction of dietary protein and progression of renal failure in diabetic nephropathy. Lancet. 1989;ii:1411-1415.
209. 209.Walker R. General mangement of end stage renal disease. B Med J. 1997;315:1429-32.
210. 210.Wang SL, Head J, Stevens L, Fuller JH. Excess mortality and its relation to hypertension and proteinuria in diabetic patients. The world health organization multinational study of vascular disease in diabetes. Diabetes Care. 1996;19(4):305-312.
211. 211.Warram JH, Laffel LMB, Valsania P, Christlieb AR, Krolewski AS. Excess mortality associated with diuretic therapy in diabetes mellitus. Arch. Intern. Med. 1991;151:1350-1356.
212. 212.Weidmann P, Boehlen LM, de Courten M, Ferrari P. Antihypertensive therapy in diabetic patients. J. Human Hypertens. 1992;6( Suppl. 2):S23-S36.
213. 213.Whelton PK. Randall B, Neaton J, Stamler J, Brancati FL, Klag MJ. Cigarette smoking and ESRD incidence in men screened for the MRFIT. J Am Soc Nephrol. 1995;6:408a.
214. 214.WHO - ISH Guidelines Subcommittee. 1999 World Health Organization - International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertension. 1999;17(2):151-183.
215. 215.World Health Organization - International Society of Hypertension Blood Pressure Lowering Treatment Trialist' Collaboration. Protocol for prospective collaborative overviews of major randomized trials of blood-pressure-lowering treatments. J Hyper. 1999;16:127-137.
216. 216.Zeller K, Whittaker E, Sullivan L, Raskin P, Jacobson HR. Effect of restricting dietary protein on the progression of renal failure in patients with insulin-dependent diabetes mellitus. N. Engl. J. Med. 1991;324:78-84.